Diana Sarfati

About Diana Sarfati

Diana Sarfati is a New Zealand cancer researcher and senior public servant. She was formerly head of the Cancer Control Agency from 2019 to 2022 and Director-General of Health from 2022 to 2025.

Occupation: academic, physician
Position held: full professor, associate professor
Citizenship: New Zealand

Family

Simon Robinsonspouse Grace Henrietta Robinsonchild Charles John Robinsonchild Lily Judith Robinsonchild

Measuring cancer survival in populations: relative survival vs cancer-specific survivalknown for The impact of comorbidity on cancer and its treatmentknown for Review of methods used to measure comorbidity in cancer populations: No gold standard existsknown for SF-36 health survey reliability, validity and norms for New Zealandknown for Survival disparities in Indigenous and non-Indigenous New Zealanders with colon cancer: the role of patient comorbidity, treatment and health service factorsknown for The effect of comorbidity on the use of adjuvant chemotherapy and survival from colon cancer: a retrospective cohort studyknown for The association of active smoking with multiple cancers: national census-cancer registry cohorts with quantitative bias analysisknown for Ethnicity and management of colon cancer in New Zealand: do indigenous patients get a worse deal?known for

Overview

Diana Sarfati (born 1967/1968) is New Zealand's Director–General of Health and a public health physician and health services researcher. She was formerly head of Te Aho o Te Kahu, the Cancer Control Agency in New Zealand. Career Sarfati was appointed Interim Chief Executive of the Cancer Control Agency on 1 December 2019, becoming the permanent chief on 1 July 2020 for what is now known as Te Aho o Te Kahu, Cancer Control Agency. In that role, she reported to the Minister and Associate Ministers of Health, and advises Government on cancer-related matters. Since being in this role, Te Aho o Te Kahu has produced a number of key reports including a state of nation in cancer report, regular reports on the impact of covid on cancer services, a cancer prevention report, and a report defining the gap in cancer medicine availability between Australia and New Zealand. Sarfati was also involved in the establishment of Peptide Receptor Radionuclide Therapy in New Zealand.

From Wikipedia (CC BY-SA 4.0).

Diana Sarfati

Diana Sarfati

Overview

Related journals

Live room · 1 here

Related journals

Overview